Elanco Animal Health is preparing to enter the corporate venture capital market with a new platform designed to identify and support emerging technologies across the animal health industry.

The company plans to launch Elanco Ventures in late 2026, backed by a multi-year commitment of $25 million. The platform will initially target early-stage businesses developing new therapeutics and supporting technologies, with priority given to companies at the pre-seed, seed and Series A stages.

Unlike a traditional internal research programme, the venture platform will give Elanco a direct route into the wider start-up ecosystem. This could help the company monitor technologies being developed outside established animal health groups while forming commercial relationships earlier in the innovation cycle.

Elanco said the platform will primarily focus on animal health but may also consider selected opportunities in the broader One Health field. It will be connected to the One Health Innovation District in Indianapolis, an ecosystem anchored by Elanco and Purdue University that brings together research, diagnostics, life sciences, talent and commercialisation capabilities.

Elanco Ventures will be overseen by corporate venture capital executive Eric Steager. The company expects the initiative to improve its visibility into emerging technologies serving both companion and production animals.

From a business perspective, the move illustrates how major animal health companies are increasingly looking beyond conventional acquisitions and internal R&D. Smaller strategic investments can provide earlier access to intellectual property, specialist teams and new technology platforms while limiting the financial exposure associated with purchasing an entire company.

According to Elanco’s official announcement, the initiative is intended to support innovation through partnerships as well as investment. For the wider animal health market, the creation of another dedicated corporate fund could also increase financing opportunities for start-ups operating in a sector where product development often requires long timelines, regulatory expertise and considerable capital.